On the apparent failure of adjuvant pelvic radiotherapy to improve survival for women with uterine sarcomas confined to the uterus

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 28, Issue 3, 2005, Pages 295-300

  Dusenbery, Kathryn E ^a,b   Potish, Roger A ^a   Argenta, Peter A ^a   Judson, Patricia L ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b Mayo Mail Code 609   (United States)

Author keywords

Leiomyosarcomas; Mixed mullerian tumors; Outcome; Radiotherapy; Uterine sarcomas

Indexed keywords

ABDOMINAL DISEASE; ABDOMINAL METASTASIS; ADJUVANT PELVIC RADIOTHERAPY; ADULT; AGED; BODY WEIGHT DISORDER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; HUMAN; INTESTINE OBSTRUCTION; LEIOMYOSARCOMA; METASTASIS; MIXED MULLERIAN TUMOR; PELVIS; PELVIS METASTASIS; REVIEW; TREATMENT FAILURE; UTERUS SARCOMA; WEIGHT REDUCTION;

ABDOMINAL NEOPLASMS; ANTINEOPLASTIC AGENTS; BRACHYTHERAPY; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DACTINOMYCIN; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; HYSTERECTOMY; IFOSFAMIDE; INTESTINAL OBSTRUCTION; LEIOMYOSARCOMA; LIFE TABLES; MIXED TUMOR, MULLERIAN; NEOPLASM STAGING; PELVIC NEOPLASMS; PERITONEAL NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; SARCOMA; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT FAILURE; UTERINE NEOPLASMS;

EID: 20444420484     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.coc.0000156919.04133.98     Document Type: Review

References (18)

1. Major FJ, Blessing JA, Silverberg SG, et al. Prognostic factors in early-stage uterine sarcoma: a Gynecologic Oncology Group Study. Cancer. 1993;71:1702-1709.
2. Omura GA, Blessing JA, Lifshitz, et al. A randomized trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group study. J Clin Oncol. 1985;3:1240-1245.
3. Reed NS, Mangioni C, Malmstrom H, et al. First results of a randomized trial comparing radiotherapy versus observation postoperatively in patients with uterine sarcomas: an EORTC-GCG study. Int J Gynecol Cancer. 2003;13:4.
4. Kempson RL, Bari W. Uterine sarcomas: classification, diagnosis, and prognosis. Hum Pathol. 1970;1:332-349.
5. FIGO. Corpus cancer staging. Int J Gynecol Obstet. 1989;28:16.
6. Kaplan EL, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc. 1958;53:457-481.
7. Fisher LD, van Belle G. Biostatistics: A Methodology for the Health Sciences. New York: John Wiley & Sons; 1984:246-303.
8. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, version 3.0, DCTD, NCI, NIH, DHHS. 2003. Available at: http://ctep.cancer.gov. Accessed May 17, 2004.
9. Hornback NB, Omura G, Major FM. Observations on the use of adjuvant radiation therapy in patients with stage I and II uterine sarcoma. Int J Radiat Oncol Biol Phys. 1986;12:2127-2130.
10. Callister M, Ramondetta LM, Jhingran A, et al. Malignant mixed mullerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome. Int J Radiat Oncol Biol Phys. 2004;58:786-796.
11. Chi DS, Mychalczak B, Saigo PE, et al. The role of whole-pelvic irradiation in the treatment of early-stage uterine carcinosarcoma. Gynecol Oncol. 1997;493-498.
12. Gerszten KG, Faul C, Koinelis S, et al. The impact of adjuvant radiotherapy on carcinosarcoma of the uterus. Gynecol Oncol. 1998;68:8-13.
13. Brooks SE, Zhan M, Cote T, et al. Surveillance, Epidemiology, and End Results analysis of 2677 cases of uterine sarcoma 1989 and 1999. Gynecol Oncol. 2004;93:204-208.
14. Perez CA, Askin F, Baglan RJ, et al. Effect of irradiation on mixed mullerian tumors of the uterus. Cancer. 1979;43:1274-1284.
15. Fleming WP, Peters WA III, Kumar NB, et al. Autopsy findings in patients with uterine sarcoma. Gynecol Oncol. 1984;19:168-172.
16. Rose PG, Piver MS, Tsukada Y, et al. Patterns of metastasis in uterine sarcoma: an autopsy study. Cancer. 1989;63:935-938.
17. Wolfson AH, Rocerto T, Bleyer A, et al. Protocol GOG #0150: a phase III randomized study of whole abdominal radiotherapy (WAR) versus combination ifosfamide-mesna with cisplatin in optimally debulked stage I, II, III, or IV carcinosarcoma (CS) of the uterus. Updated 2004. Available at: http://www.gog.org. Accessed May 17, 2004.
18. Fleiss JL. Statistical Methods for Rates and Proportions, 2nd ed. New York: John Wiley & Sons; 1981:33-49, 260-280.